Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12929187 | 1.00 | MEN1 (0.46) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL26765756 | 0.88 | MEN1 (0.43) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL7153011 | 0.86 | MEN1 (0.51) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL7145829 | 0.86 | MEN1 (0.51) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL8905280 | 0.82 | MEN1 (0.49) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL8905152 | 0.82 | MEN1 (0.49) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL8905004 | 0.82 | MEN1 (0.49) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL19905641 | 0.82 | MEN1 (0.45) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL17879635 | 0.81 | MEN1 (0.48) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL29306409 | 0.79 | MEN1 (0.42) | MEN1KMT2AL3MBTL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1947092-B1 | Method for producing nucleic acid base having perfluoroalkyl group | TOSOH CORP (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-7884202-B2 | Nucleobases are perfluoroalkylated in a one step process with a perfluoroalkyl halide in the presence of a sulfoxide, a peroxide and an iron compound; useful as medicinal drugs, intermediates for medicinal drugs and agricultural chemicals | TOSOH CORPORATION (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20090124796-A1 | Nucleobase Having Perfluoroalkyl Group and Process for Producing the Same | TOSOH CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124796-A1 | Nucleobase Having Perfluoroalkyl Group and Process for Producing the Same | PFAS, FPGS, NUDT1 | MEN1 4291/4885KMT2A 1473/4885L3MBTL1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.